Aimed Bio Inc. (KOSDAQ:0009K0)

South Korea flag South Korea · Delayed Price · Currency is KRW
47,550
+1,250 (2.70%)
At close: Apr 10, 2026
Market Cap3.08T
Revenue (ttm)94.56B +302.0%
Net Income-212.45M
EPS101.00
Shares Out64.67M
PE Ration/a
Forward PE279.71
Dividendn/a
Ex-Dividend Daten/a
Volume129,235
Average Volume340,497
Open47,400
Previous Close46,300
Day's Range46,100 - 47,900
52-Week Range42,000 - 80,200
Betan/a
RSI42.24
Earnings DateApr 13, 2026

About Aimed Bio

Aimed Bio Inc. develops therapeutic solutions for patients with brain diseases, including neuro-oncological and degenerative diseases. Its multidisciplinary platform offers antibody-drug conjugates, blood-brain barrier penetration, brain immune modulation, and patient-derived models (PDC/PDX). Aimed Bio Inc. was founded in 2018 and is based in Seoul, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2018
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 0009K0
Full Company Profile

Financial Performance

In 2025, Aimed Bio's revenue was 94.56 billion, an increase of 302.02% compared to the previous year's 23.52 billion. Losses were -212.45 million, -96.70% less than in 2024.

Financial Statements